Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT05101629 |
Title | Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab Therapy |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | DEU |